Repligen Corporation, a life sciences company, has acquired 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.

The addition of these desktop assets complements and strengthens Repligen’s differentiated PAT portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies.

Products acquired from 908 Devices include:

• MAVERICK and MAVEN for real-time monitoring and control of critical bioprocess parameters
• REBEL, an at-line cell culture media analyzer
• ZipChip, a high-resolution sample separations device used in the characterization of product quality attributes

Olivier Loeillot, President and CEO at Repligen said, “We are really excited to onboard the 908 bioprocessing team and the four differentiated upstream PAT technologies that are commercialized today. They are the perfect complement to our downstream analytics portfolio and will enable Repligen to further penetrate a broad set of modalities and offer analytics solutions across the entire bioprocess workflow. This asset acquisition is a true win-win for both organizations, and a significant step forward for Repligen as our customers increasingly embed digitization technologies in their production processes.”

“Repligen’s leadership in commercializing innovative solutions that advance bioprocessing is a great fit for our novel desktop devices and our bioprocessing team. I wish them continued success,” said Kevin J. Knopp, CEO and Co-founder, 908 Devices.

The purchase consideration is a payment of $70 million in cash.

More Pharma Industry Acquisitions

Don’t miss Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.